Methven recommendation lifted on earnings potential from Chinese acquisition
First NZ Capital raises its target price after the tapware maker agrees to buy manufacturer Invention Sanitary.
First NZ Capital raised its target price on Methven after the tapware maker agreed to buy its Chinese manufacturer Invention Sanitary.
The brokerage, which has an 'outperform' recommendation on the stock, raised its 12-month target price to $1.50 from $1.35 on the expectation the purchase will boost earnings,it says in a note.
It lowered its expectations for the company's 2014 earnings before interest, tax, depreciation and amortisation by 2.9 percent to take account of higher New Zealand margins and lower earnings from Australia.
However, it raised expectations for 2015 earnings, as the benefits from the Chinese acquisition are expected to offset lower Australian income.
"Methven remains a good company being buffeted by some tough markets in Australia and the UK, while New Zealand appears to be slowly improving," First NZ says in the note. "The proposed acquisition of Invention Sanitary seems logical and will provide a nice earnings growth profile for FY15 and FY16."
First NZ's target price is a discount to its $1.73 discounted cash flow valuation because of near-term concerns about trading conditions and the length of time until benefits from the acquisition flow through, the brokerage says.
Shares in Methven last traded at $1.34 and have declined 2.2 percent so far this year.
(BusinessDesk)
Tina Morrison
Wed, 11 Jul 2018
Wed, 11 Jul 2018
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Methven recommendation lifted on earnings potential from Chinese acquisition
31279